ClinicalTrials.Veeva
Menu

Find clinical trials for Prostate Cancer in New Haven, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Prostatic Cancer
Cancer
Carcinoma
Hypersensitivity
Endometrial Cancer
Breast Cancer
Recurrence

Prostate Cancer trials near New Haven, CT, USA:

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP)

androgen deprivation therapy (ADT) with a luteinising hormone releasing hormone analogue (LHRHA) in men having radiation therapy for localised prostate...

Active, not recruiting
Prostate Cancer
Drug: Placebo oral tablet
Drug: Luteinizing Hormone-Releasing Hormone Analog

Phase 3

University of Sydney

Commack, New York, United States and 92 other locations

pharmacodynamic (PD), and the preliminary efficacy of JANX007 administered as a single agent in adults with metastatic castration-resistant prostate...

Enrolling
Castration Resistant Prostatic Cancer
Metastatic Castration-resistant Prostate Cancer
Biological: JANX007

Phase 1

Janux Therapeutics

New Haven, Connecticut, United States and 15 other locations

Phase 1b study to assess the combination of ARV-110 and abiraterone in patients with metastatic prostate cancer with rising PSA val...

Active, not recruiting
Prostate Cancer Metastatic
Drug: ARV-110 in Combination with Abiraterone

Phase 1

Arvinas
Arvinas

New Haven, Connecticut, United States and 17 other locations

Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate...

Enrolling
Prostate Adenocarcinoma
Prostate Cancer
Drug: Copper Cu 64 PSMA I&T

Phase 3

Curium

Hawthorne, New York, United States and 34 other locations

A Phase 1/2 study to evaluate the safety and efficacy of ARV-766 given by mouth alone or in combination with abiraterone in men with metastatic prostate...

Enrolling
Prostate Cancer Metastatic
Drug: ARV-766 + Abiraterone Part C&D
Drug: ARV-766 Part A&B

Phase 1, Phase 2

Arvinas
Arvinas

New Haven, Connecticut, United States and 22 other locations

is a safe and effective way to treat previously untreated metastatic prostate cancer, and to see whether the study treatment works ...

Active, not recruiting
Metastatic Prostate Cancer
Drug: Abiraterone
Drug: Prednisone

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Commack, New York, United States and 7 other locations

Phase 1/2 dose escalation study to assess the safety and tolerability of ARV-110 in men with mCRPC who have progressed on prior approved systemic the...

Active, not recruiting
Prostate Cancer Metastatic
Drug: ARV-110

Phase 1, Phase 2

Arvinas
Arvinas

New Haven, Connecticut, United States and 53 other locations

Evaluate the safety and tolerability of AMG 509 in adult participants and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2...

Enrolling
Prostate Cancer
Drug: Abiraterone
Drug: Enzalutamide

Phase 1

Amgen
Amgen

New Haven, Connecticut, United States and 52 other locations

to as AAA617. The study also seeks to further characterize (as possible) any other serious adverse reaction(s) in the long-term in adults with prostate...

Enrolling
Prostate Cancer
Drug: AAA617

Phase 4

Novartis
Novartis

Hartford, Connecticut, United States and 53 other locations

This study is comparing the safety and effectiveness of abiraterone acetate alone, followed by the addition of prednisone (when the participant's dis...

Active, not recruiting
Castration-resistant Prostate Cancer
Drug: abiraterone acetate

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Commack, New York, United States and 7 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems